Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI

American Heart Journal

Volumn 192, Issue , 2017, Pages 105-112

  Dehghani, Payam ^a   Lavoie, Andrea ^a   Lavi, Shahar ^b   Crawford, Jennifer J ^a   Harenberg, Sebastian ^a   Zimmermann, Rodney H ^a   Booker, Jeff ^a   Kelly, Sheila ^a   Cantor, Warren J ^c   Mehta, Shamir R ^d   Bagai, Akshay ^e   Goodman, Shaun G ^e   Cheema, Asim N ^e  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOLYTIC AGENT; TENECTEPLASE; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADD ON THERAPY; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BRADYCARDIA; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG FATALITY; DYSPNEA; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; HYPOTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCULOSKELETAL PAIN; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PERFORATION; PHASE 3 CLINICAL TRIAL; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUDDEN CARDIAC DEATH; TACHYCARDIA; THORAX PAIN; THROMBOCYTE FUNCTION; URINARY TRACT INFECTION; URTICARIA; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; MULTICENTER STUDY; PREOPERATIVE CARE; PROCEDURES; PROGNOSIS; ST ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; TIME FACTOR;

ADENOSINE; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; ST ELEVATION MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY; TICLOPIDINE; TIME FACTORS;

EID: 85027882335     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.07.013     Document Type: Article

References (29)

1. O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127:4 (2013), 529–555.
2. Hsia, R.Y., Shen, Y.C., Percutaneous coronary intervention in the United States: risk factors for untimely access. Health Serv Res 51:2 (2016), 592–609.
3. Armstrong, P.W., Boden, W.E., Reperfusion paradox in ST-segment elevation myocardial infarction. Ann Intern Med 155:6 (2011), 389–391.
4. Bates, E.R., Nallamothu, B.K., Commentary: the role of percutaneous coronary intervention in ST-segment-elevation myocardial infarction. Circulation 118:5 (2008), 567–573.
5. Gandhi, S., Zile, B., Tan, M.K., et al. Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. Can J Cardiol 30:12 (2014), 1725–1731.
6. Cantor, W.J., Fitchett, D., Borgundvaag, B., et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 360:26 (2009), 2705–2718.
7. Borgia, F., Goodman, S.G., Halvorsen, S., et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J 31:17 (2010), 2156–2169.
8. Fernandez-Aviles, F., Alonso, J.J., Castro-Beiras, A., et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 364:9439 (2004), 1045–1053.
9. Steg, P.G., James, S., Harrington, R.A., et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122:21 (2010), 2131–2141.
10. Diego, A., de Prado, A.P., Cuellas, C., et al. P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction. Thromb Res 130:3 (2012), e31–6.
11. Stone, G.W., Witzenbichler, B., Weisz, G., et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:9892 (2013), 614–623.
12. Campo, G., Parrinello, G., Ferraresi, P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:25 (2011), 2474–2483.
13. Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:11 (2009), 1045–1057.
14. Tantry, U.S., Bonello, L., Aradi, D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62:24 (2013), 2261–2273.
15. Angiolillo, D.J., Capranzano, P., Goto, S., et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 29:18 (2008), 2202–2211.
16. Angiolillo, D.J., Badimon, J.J., Saucedo, J.F., et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 32:7 (2011), 838–846.
17. Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:23 (2011), 2736–2747.
18. Storey, R.F., Angiolillo, D.J., Patil, S.B., et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56:18 (2010), 1456–1462.
19. Gurbel, P.A., Bliden, K.P., Butler, K., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:25 (2009), 2577–2585.
20. Serebruany, V.L., Malinin, A.I., Callahan, K.P., et al. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. Am Heart J 145:4 (2003), 636–642.
21. Gawaz, M., Neumann, F.J., Ott, I., et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93:2 (1996), 229–237.
22. Alexopoulos, D., Xanthopoulou, I., Gkizas, V., et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5:6 (2012), 797–804.
23. Valgimigli, M., Tebaldi, M., Campo, G., et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 5:3 (2012), 268–277.
24. Alexopoulos, D., Perperis, A., Koniari, I., et al. Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. J Thromb Thrombolysis 40:3 (2015), 261–267.
25. Goudevenos, J., Ntalas, I., Xanthopoulou, I., et al. Use of ticagrelor in patients with ST-elevation myocardial infarction undergoing thrombolysis. J Thromb Thrombolysis, 2013.
26. Aradi, D., Komocsi, A., Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?. Platelets 23:3 (2012), 167–176.
27. Price, M.J., Berger, P.B., Teirstein, P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:11 (2011), 1097–1105.
28. Tanswell, P., Modi, N., Combs, D., et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 41:15 (2002), 1229–1245.
29. Frelinger, A.L. III, Bhatt, D.L., Lee, R.D., et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 61:8 (2013), 872–879.